4539 Stock Overview
Engages in the manufacture, sale, import, and export of ethical pharmaceuticals and diagnostic agents in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
Nippon Chemiphar Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥1,422.00 |
| 52 Week High | JP¥1,700.00 |
| 52 Week Low | JP¥1,422.00 |
| Beta | 0.15 |
| 1 Month Change | -6.45% |
| 3 Month Change | -5.26% |
| 1 Year Change | -11.01% |
| 3 Year Change | -30.33% |
| 5 Year Change | -46.24% |
| Change since IPO | -85.78% |
Recent News & Updates
Nippon Chemiphar (TSE:4539) Is Paying Out A Dividend Of ¥50.00
Dec 03
Nippon Chemiphar (TSE:4539) Is Due To Pay A Dividend Of ¥50.00
Nov 03Shareholder Returns
| 4539 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -4.2% | 0.003% | 1.4% |
| 1Y | -11.0% | 3.0% | 7.4% |
Return vs Industry: 4539 underperformed the JP Pharmaceuticals industry which returned 3% over the past year.
Return vs Market: 4539 underperformed the JP Market which returned 7.4% over the past year.
Price Volatility
| 4539 volatility | |
|---|---|
| 4539 Average Weekly Movement | 2.0% |
| Pharmaceuticals Industry Average Movement | 3.9% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in JP Market | 7.4% |
| 10% least volatile stocks in JP Market | 1.8% |
Stable Share Price: 4539 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4539's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1950 | 887 | Kazushiro Yamaguchi | www.chemiphar.co.jp |
Nippon Chemiphar Co., Ltd., together with its subsidiaries, engages in the manufacture, sale, import, and export of ethical pharmaceuticals and diagnostic agents in Japan and internationally. the company offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels, as well as 57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements. It also develops NC-2400, a PPAR-delta agonist currently under phase 1 development; NC-2500, a XOR inhibitor for the treatment of hyperuricemia/gout currently under phase 1 development; and NC-2600, a P2X4 receptor antagonist for the treatment of neuropathic pain currently under phase 1 development.
Nippon Chemiphar Co., Ltd. Fundamentals Summary
| 4539 fundamental statistics | |
|---|---|
| Market cap | JP¥5.13b |
| Earnings (TTM) | -JP¥255.00m |
| Revenue (TTM) | JP¥31.54b |
0.2x
P/S Ratio-20.1x
P/E RatioIs 4539 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4539 income statement (TTM) | |
|---|---|
| Revenue | JP¥31.54b |
| Cost of Revenue | JP¥23.32b |
| Gross Profit | JP¥8.22b |
| Other Expenses | JP¥8.48b |
| Earnings | -JP¥255.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 31, 2025
| Earnings per share (EPS) | -70.67 |
| Gross Margin | 26.07% |
| Net Profit Margin | -0.81% |
| Debt/Equity Ratio | 96.6% |
How did 4539 perform over the long term?
See historical performance and comparisonDividends
3.5%
Current Dividend Yield-71%
Payout RatioDoes 4539 pay a reliable dividends?
See 4539 dividend history and benchmarks| Nippon Chemiphar dividend dates | |
|---|---|
| Ex Dividend Date | Mar 28 2025 |
| Dividend Pay Date | Jun 24 2025 |
| Days until Ex dividend | 56 days |
| Days until Dividend pay date | 144 days |
Does 4539 pay a reliable dividends?
See 4539 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 18:05 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nippon Chemiphar Co., Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Fumiyoshi Sakai | Credit Suisse |
| Motoya Kohtani | Nomura Securities Co. Ltd. |
| Pravin Gondhale | Virtua Research Inc. |